US20190110974A1 - Kits and methods of using ascorbates to modify polysaccharide fillers and delivery systems - Google Patents
Kits and methods of using ascorbates to modify polysaccharide fillers and delivery systems Download PDFInfo
- Publication number
- US20190110974A1 US20190110974A1 US16/097,941 US201716097941A US2019110974A1 US 20190110974 A1 US20190110974 A1 US 20190110974A1 US 201716097941 A US201716097941 A US 201716097941A US 2019110974 A1 US2019110974 A1 US 2019110974A1
- Authority
- US
- United States
- Prior art keywords
- polysaccharide
- mass
- ascorbate
- kit
- drug delivery
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/58—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/88—Two- or multipart kits
- A61K2800/882—Mixing prior to application
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/91—Injection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/06—Flowable or injectable implant compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/34—Materials or treatment for tissue regeneration for soft tissue reconstruction
Definitions
- Embodiments of the present invention were not conceived or reduced to practice with Federal sponsorship.
- Polysaccharides are used as cosmetic fillers and as a component of injectable drug delivery systems. When polysaccharides are placed in the body as a filler or as a drug delivery system, the polysaccharides may have a long period of time before such are resorbed into the body through metabolism or other means.
- Embodiments of the present invention facilitate the use of polysaccharides, particularly as such polysaccharides are used as fillers and drug delivery vehicles.
- Embodiments of the present invention allow the polysaccharide to be modified in vivo or in vitro to impart special physical and chemical properties. For example, without limitation, the physical properties of texture, feel, resistance to pressure, viscosity and the like can be altered or modified, in vivo or in vitro. Similarly, the chemical properties, resistance to degradation and speed, of degradation can be modified or altered.
- polysaccharide fillers used for cosmetic purposes typically comprise solutions of 1.0 to 5.0%. These solutions may also comprise other materials to improve the flow or feel of the filler, such as hyaluronic acid, and anesthetic agents to address the potential discomfort during the administration of the filler. Anesthetic agents are well known in the art and include, without limitation, lidocaine. These fillers are administered to the deep layer of the skin. An example of a filler of this type is described in PCT/IB2014/060322 to Ghimas SPA, the entire content of which is incorporated herein by reference.
- One embodiment of the present invention is directed to a method of altering or modifying a mass comprising a polysaccharide held in the body of an animal.
- the method comprises the steps of administering an effective amount of ascorbate to the mass.
- the ascorbate can be administered to the mass prior to the mass being placed in the body or after the mass has been placed in the body.
- One embodiment of the method features a polysaccharide having one or more sugars selected from the group consisting of D-galactose and 3, 6-anhydro-L-galactopyranose. These sugars are the constituents of agarose. Agarose is used as a dermal filler and as a drug delivery vehicle. As used herein, a “drug delivery vehicle” comprises a polysaccharide and one or more drugs.
- the term “ascorbate” refers to ascorbic acid and its salts and oxidized forms such as dehydroascorbic acid. Ascorbic acid is commonly known as Vitamin C. As used herein, ascorbate refers to both the levo and dextro forms. Ascorbate alters the form of the polysaccharide, increasing its dissolution, breaking down and fluidizing the mass. One embodiment of the present invention features an injectable ascorbic acid, such as Vitamin C. As used herein, the term “an effective amount” refers to an amount to cause the polysaccharide to assume a desired fluidized form. The desired fluidized form refers to an more fluid form compared to agarose of same polymer composition and hydration without an ascorbate being present.
- the ascorbate has utility to facilitate removal of the polysaccharide, control the delivery or release of drug, address hardness, graininess or nodules in the mass and minimize the mark on the skin from the injection of drug.
- a drug delivery system comprises a polysaccharide and an ascorbate held in a vessel for reconstitution. Upon reconstitution, the ascorbate maintains the polysaccharide in a more fluid state. This fluid may continue after injection of the drug delivery system into a patient.
- drug is used to refer to any compound or compounds used to effect a biological change or treat a medical condition.
- the drug may be incorporated into the polysaccharide prior to reconstitution or after reconstitution.
- examples of drugs include without limitation, lidocaine, and other anesthetic agents, onabotulinemtoxin A (BOTOX®, Allergan) and other aesthetic agents.
- a further embodiment of the present invention is directed to a kit for performing dermal filling procedures or for the administration of drug.
- the kit comprises a polysaccharide for forming a mass in the body of an animal and an ascorbate for maintaining or making the polysaccharide more fluid for administration to the mass held in the body to effect a modification or speeding the resorption of said mass.
- One embodiment of the present kit features a polysaccharide having one or more sugars selected from the group consisting of D-galactose and 3, 6-anhydro-L-galactopyranose. These sugars are constituents of the polysaccharide, agarose.
- FIG. 1 depicts a kit embodying features of the present invention.
- Embodiments of the present invention will now be described in detail with respect to a kit for performing dermal filling procedures or for the administration of drug.
- the present description is directed to embodiments which are considered to be the best mode to practice the present invention at the time of the writing of the present description.
- Those skilled in the art will recognize that the understanding of the best mode may change in time.
- Those skilled in the art will also recognize that the features of the present invention described are subject to alteration and modification and such that the present discussion should not be considered limiting.
- kit 11 a kit, generally designated by the numeral 11 , embodying features of the present invention is depicted.
- the term “kit” is used to denote a bundled assembly of parts and constituents for performing a method.
- the kit 11 comprises two vials, a first vial 13 containing a polysaccharide for forming a mass in the body of an animal and a second vial 15 containing an ascorbate for fluidizing the polysaccharide for administration to the mass held in the body.
- the first vial 13 and second vial 15 are bundled or held in a package 17 with means for administering the polysaccharide and means for administering the enzyme, in the form of first syringe 19 and second syringe 21 , and instructions 23 .
- the first vial 13 contains a polysaccharide for forming a mass in the body of an animal or patient.
- the polysaccharide can be pre-made and in a final form ready for administration or be lyophilized for reconstitution with water.
- the first syringe 19 is used to withdraw the reconstituted or pre-made polysaccharide for injection into an animal or patient.
- a human subject may use the mass to conceal wrinkles or to build bulk to areas of the body showing signs of atrophy or for which a fuller appearance is desired.
- the present kit features a polysaccharide having one or more sugars selected from the group consisting of D-galactose and 3, 6-anhydro-L-galactopyranose. These sugars are constituents of the polysaccharide, agarose, which is used as a dermal filler. Agarose is sold as a dermal filler under the mark ALGINESS®.
- the second vial 15 contains an ascorbate to effect a modification or speeding the resorption or altering the fluidity of the mass.
- the ascorbate can be pre-made and in a final form ready for administration or be lyophilized for reconstitution with water.
- the second syringe 21 is used to withdraw the reconstituted or pre-made ascorbate for injection into the mass.
- the subject may desire the mass to have a softer feel, or the mass may exhibit graininess or nodules.
- the ascobate is placed in the mass and the mass manipulated to distribute the ascorbate where the ascorbate may effect a modification of the polysaccharide.
- the polysaccharide assumes a more fluid form, capable of faster metabolisation, removing graininess and nodules and presenting a softens the mass.
- Ascorbic acid is available in injectable forms from numerous suppliers. Mylan Institutional LLC (Rockland, Ill. 61103) sells Ascorbic Acid for Injection 500 mg/ml. The monogram for ascorbic acid suggests that doses of ascorbic acid up to 6 grams are tolerated.
- Embodiments of the present invention facilitate the use of polysaccharides, particularly as such polysaccharides are used as fillers and drug delivery vehicles.
- Embodiments of the present invention allow the polysaccharide to be modified in vivo or in vitro to impart special physical and chemical properties. That is, the ascorbate can be distributed into the polysaccharide prior to administration of the polysaccharide or after administration of the polysaccharide to create a desired physical property of texture, feel, resistance to pressure, viscosity and the like.
- the chemical properties of resistance to degradation and speed of degradation can be modified or altered.
- the modification of physical and chemical features of a polysaccharide used as a filler or drug delivery system allows the health practitioner to modify the filler mass after it has been placed in the body or prior to placement in the body.
- the mass may be fluidized for removal or minimization by withdrawing the mass after the administration of the ascorbate.
- the fluidization of the mass allows the mass to be redistributed and aids in the resorption of the mass.
- kit 11 and the instructions 23 will now be described with respect to an embodiment of the present invention directed to a method of altering or modifying a mass comprising a polysaccharide held in the body of an animal.
- the instructions 23 direct the user to reconstitute the polysaccharide held in first vial 13 and the ascorbate held in second vial 15 if reconstitution is needed.
- the instructions 23 direct the user to administer polysaccaride held in the first vial 13 .
- the instructions 23 further direct the user to administer an effective amount of an ascorbate for the polysaccharide to the mass.
- the ascorbate can be administered to the mass prior to the mass being placed in the body or after the mass has been placed in the body.
- More than one application of ascorbate may be used to obtain the desired consistency of the mass.
- the mass may be gently kneaded or manipulated to distribute the ascorbate throughout the mass structure.
- the fluidized mass may be manipulated into a desired position or removed by suction through the same syringe administering the ascorbate.
- Embodiments of the method and kits feature a polysaccharide having one or more sugars selected from the group consisting of D-galactose and 3, 6-anhydro-L-galactopyranose. These sugars are the constituents of agarose. Agarose is used as a dermal filler and as a drug delivery vehicle.
- Embodiments of the method and kits features an ascorbate, ascorbic acid, Vitamin C.
- Ascorbic acid is well tolerates and the amount based on the mass of polysaccharide.
- Monographs for such enzymes are available from the respective manufacturers and are
Abstract
Description
- This application claims priority to U.S. Provisional Application No. 62/355,086, filed Jun. 27, 2016. The contents of the entire application are incorporated by reference.
- Embodiments of the present invention were not conceived or reduced to practice with Federal sponsorship.
- Polysaccharides are used as cosmetic fillers and as a component of injectable drug delivery systems. When polysaccharides are placed in the body as a filler or as a drug delivery system, the polysaccharides may have a long period of time before such are resorbed into the body through metabolism or other means.
- Embodiments of the present invention facilitate the use of polysaccharides, particularly as such polysaccharides are used as fillers and drug delivery vehicles. Embodiments of the present invention allow the polysaccharide to be modified in vivo or in vitro to impart special physical and chemical properties. For example, without limitation, the physical properties of texture, feel, resistance to pressure, viscosity and the like can be altered or modified, in vivo or in vitro. Similarly, the chemical properties, resistance to degradation and speed, of degradation can be modified or altered.
- The modification of physical and chemical features of a polysaccharide used as a filler or drug delivery system allows the health practitioner to modify the filler mass after it has been placed in the body or prior to placement in the body. As used herein, the term, “mass” refers to the polysaccharide material and the surrounding space it occupies. For example, polysaccharide fillers used for cosmetic purposes typically comprise solutions of 1.0 to 5.0%. These solutions may also comprise other materials to improve the flow or feel of the filler, such as hyaluronic acid, and anesthetic agents to address the potential discomfort during the administration of the filler. Anesthetic agents are well known in the art and include, without limitation, lidocaine. These fillers are administered to the deep layer of the skin. An example of a filler of this type is described in PCT/IB2014/060322 to Ghimas SPA, the entire content of which is incorporated herein by reference.
- One embodiment of the present invention is directed to a method of altering or modifying a mass comprising a polysaccharide held in the body of an animal. The method comprises the steps of administering an effective amount of ascorbate to the mass. The ascorbate can be administered to the mass prior to the mass being placed in the body or after the mass has been placed in the body.
- One embodiment of the method features a polysaccharide having one or more sugars selected from the group consisting of D-galactose and 3, 6-anhydro-L-galactopyranose. These sugars are the constituents of agarose. Agarose is used as a dermal filler and as a drug delivery vehicle. As used herein, a “drug delivery vehicle” comprises a polysaccharide and one or more drugs.
- As used herein, the term “ascorbate” refers to ascorbic acid and its salts and oxidized forms such as dehydroascorbic acid. Ascorbic acid is commonly known as Vitamin C. As used herein, ascorbate refers to both the levo and dextro forms. Ascorbate alters the form of the polysaccharide, increasing its dissolution, breaking down and fluidizing the mass. One embodiment of the present invention features an injectable ascorbic acid, such as Vitamin C. As used herein, the term “an effective amount” refers to an amount to cause the polysaccharide to assume a desired fluidized form. The desired fluidized form refers to an more fluid form compared to agarose of same polymer composition and hydration without an ascorbate being present.
- Wherein the mass is a delivery vehicle for one or more drugs, the ascorbate has utility to facilitate removal of the polysaccharide, control the delivery or release of drug, address hardness, graininess or nodules in the mass and minimize the mark on the skin from the injection of drug. For example, without limitation, one embodiment of an invention directed to a drug delivery system comprises a polysaccharide and an ascorbate held in a vessel for reconstitution. Upon reconstitution, the ascorbate maintains the polysaccharide in a more fluid state. This fluid may continue after injection of the drug delivery system into a patient. As used herein, the term “drug” is used to refer to any compound or compounds used to effect a biological change or treat a medical condition. The drug may be incorporated into the polysaccharide prior to reconstitution or after reconstitution. Examples of drugs include without limitation, lidocaine, and other anesthetic agents, onabotulinemtoxin A (BOTOX®, Allergan) and other aesthetic agents.
- A further embodiment of the present invention is directed to a kit for performing dermal filling procedures or for the administration of drug. The kit comprises a polysaccharide for forming a mass in the body of an animal and an ascorbate for maintaining or making the polysaccharide more fluid for administration to the mass held in the body to effect a modification or speeding the resorption of said mass.
- One embodiment of the present kit features a polysaccharide having one or more sugars selected from the group consisting of D-galactose and 3, 6-anhydro-L-galactopyranose. These sugars are constituents of the polysaccharide, agarose.
- These and other features and advantages will be apparent to those skilled in the art upon viewing the figure which is briefly described below and studying the details description that follows.
-
FIG. 1 depicts a kit embodying features of the present invention. - Embodiments of the present invention will now be described in detail with respect to a kit for performing dermal filling procedures or for the administration of drug. The present description is directed to embodiments which are considered to be the best mode to practice the present invention at the time of the writing of the present description. Those skilled in the art will recognize that the understanding of the best mode may change in time. Those skilled in the art will also recognize that the features of the present invention described are subject to alteration and modification and such that the present discussion should not be considered limiting.
- Turning now to
FIG. 1 , a kit, generally designated by thenumeral 11, embodying features of the present invention is depicted. The term “kit” is used to denote a bundled assembly of parts and constituents for performing a method. Thekit 11 comprises two vials, afirst vial 13 containing a polysaccharide for forming a mass in the body of an animal and asecond vial 15 containing an ascorbate for fluidizing the polysaccharide for administration to the mass held in the body. Thefirst vial 13 andsecond vial 15 are bundled or held in apackage 17 with means for administering the polysaccharide and means for administering the enzyme, in the form offirst syringe 19 andsecond syringe 21, andinstructions 23. - The
first vial 13 contains a polysaccharide for forming a mass in the body of an animal or patient. The polysaccharide can be pre-made and in a final form ready for administration or be lyophilized for reconstitution with water. Thefirst syringe 19 is used to withdraw the reconstituted or pre-made polysaccharide for injection into an animal or patient. For example, a human subject may use the mass to conceal wrinkles or to build bulk to areas of the body showing signs of atrophy or for which a fuller appearance is desired. - The present kit features a polysaccharide having one or more sugars selected from the group consisting of D-galactose and 3, 6-anhydro-L-galactopyranose. These sugars are constituents of the polysaccharide, agarose, which is used as a dermal filler. Agarose is sold as a dermal filler under the mark ALGINESS®.
- The
second vial 15 contains an ascorbate to effect a modification or speeding the resorption or altering the fluidity of the mass. The ascorbate can be pre-made and in a final form ready for administration or be lyophilized for reconstitution with water. Thesecond syringe 21 is used to withdraw the reconstituted or pre-made ascorbate for injection into the mass. For example, in a human subject using the mass to conceal wrinkles or to build bulk to areas of the body showing signs of atrophy, the subject may desire the mass to have a softer feel, or the mass may exhibit graininess or nodules. The ascobate is placed in the mass and the mass manipulated to distribute the ascorbate where the ascorbate may effect a modification of the polysaccharide. The polysaccharide assumes a more fluid form, capable of faster metabolisation, removing graininess and nodules and presenting a softens the mass. Ascorbic acid is available in injectable forms from numerous suppliers. Mylan Institutional LLC (Rockland, Ill. 61103) sells Ascorbic Acid for Injection 500 mg/ml. The monogram for ascorbic acid suggests that doses of ascorbic acid up to 6 grams are tolerated. - Embodiments of the present invention facilitate the use of polysaccharides, particularly as such polysaccharides are used as fillers and drug delivery vehicles. Embodiments of the present invention allow the polysaccharide to be modified in vivo or in vitro to impart special physical and chemical properties. That is, the ascorbate can be distributed into the polysaccharide prior to administration of the polysaccharide or after administration of the polysaccharide to create a desired physical property of texture, feel, resistance to pressure, viscosity and the like. Similarly, the chemical properties of resistance to degradation and speed of degradation can be modified or altered.
- The modification of physical and chemical features of a polysaccharide used as a filler or drug delivery system allows the health practitioner to modify the filler mass after it has been placed in the body or prior to placement in the body. For example, the mass may be fluidized for removal or minimization by withdrawing the mass after the administration of the ascorbate. The fluidization of the mass allows the mass to be redistributed and aids in the resorption of the mass.
- The use of the
kit 11 and theinstructions 23 will now be described with respect to an embodiment of the present invention directed to a method of altering or modifying a mass comprising a polysaccharide held in the body of an animal. Theinstructions 23 direct the user to reconstitute the polysaccharide held infirst vial 13 and the ascorbate held insecond vial 15 if reconstitution is needed. Theinstructions 23 direct the user to administer polysaccaride held in thefirst vial 13. Theinstructions 23 further direct the user to administer an effective amount of an ascorbate for the polysaccharide to the mass. The ascorbate can be administered to the mass prior to the mass being placed in the body or after the mass has been placed in the body. More than one application of ascorbate may be used to obtain the desired consistency of the mass. The mass may be gently kneaded or manipulated to distribute the ascorbate throughout the mass structure. The fluidized mass may be manipulated into a desired position or removed by suction through the same syringe administering the ascorbate. - Embodiments of the method and kits feature a polysaccharide having one or more sugars selected from the group consisting of D-galactose and 3, 6-anhydro-L-galactopyranose. These sugars are the constituents of agarose. Agarose is used as a dermal filler and as a drug delivery vehicle.
- Embodiments of the method and kits features an ascorbate, ascorbic acid, Vitamin C. Ascorbic acid is well tolerates and the amount based on the mass of polysaccharide. Monographs for such enzymes are available from the respective manufacturers and are
Claims (14)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/097,941 US20190110974A1 (en) | 2016-06-27 | 2017-06-27 | Kits and methods of using ascorbates to modify polysaccharide fillers and delivery systems |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662355086P | 2016-06-27 | 2016-06-27 | |
PCT/US2017/039506 WO2018005494A1 (en) | 2016-06-27 | 2017-06-27 | Kits and methods of using ascorbates to modify polysaccharide fillers and delivery systems |
US16/097,941 US20190110974A1 (en) | 2016-06-27 | 2017-06-27 | Kits and methods of using ascorbates to modify polysaccharide fillers and delivery systems |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2017/039506 A-371-Of-International WO2018005494A1 (en) | 2016-06-27 | 2017-06-27 | Kits and methods of using ascorbates to modify polysaccharide fillers and delivery systems |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/125,572 Division US20210228468A1 (en) | 2016-06-27 | 2020-12-17 | Kits and methods of using ascorbates to modify polysaccharide fillers and delivery systems |
Publications (1)
Publication Number | Publication Date |
---|---|
US20190110974A1 true US20190110974A1 (en) | 2019-04-18 |
Family
ID=60785516
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/097,941 Abandoned US20190110974A1 (en) | 2016-06-27 | 2017-06-27 | Kits and methods of using ascorbates to modify polysaccharide fillers and delivery systems |
US17/125,572 Pending US20210228468A1 (en) | 2016-06-27 | 2020-12-17 | Kits and methods of using ascorbates to modify polysaccharide fillers and delivery systems |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/125,572 Pending US20210228468A1 (en) | 2016-06-27 | 2020-12-17 | Kits and methods of using ascorbates to modify polysaccharide fillers and delivery systems |
Country Status (3)
Country | Link |
---|---|
US (2) | US20190110974A1 (en) |
EP (1) | EP3364942A4 (en) |
WO (1) | WO2018005494A1 (en) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007019554A2 (en) * | 2005-08-08 | 2007-02-15 | Momenta Pharmaceuticals, Inc. | Polysaccharides for delivery of active agents |
EP2484387A1 (en) * | 2011-02-03 | 2012-08-08 | Q-Med AB | Hyaluronic acid composition |
ITMI20130507A1 (en) * | 2013-04-04 | 2014-10-05 | Ghimas Spa | FILLING COMPOSITION (FILLER) FOR THE TREATMENT OF LIPOATROPHIES |
US9388252B2 (en) * | 2014-02-17 | 2016-07-12 | Aurelien Forget | Methods for purifying polysaccharides and pharmaceutical compositions and medical devices containing the same |
US10413491B2 (en) * | 2014-04-02 | 2019-09-17 | Merz Pharma Gmbh & Co. Kgaa | In vivo accelerated degradation of polysaccharide-containing fillers |
WO2015155639A1 (en) * | 2014-04-08 | 2015-10-15 | Red Gold Agarose Corp. | A gel-like agarose admixture for intermediate cosmetics product |
-
2017
- 2017-06-27 EP EP17821075.3A patent/EP3364942A4/en active Pending
- 2017-06-27 US US16/097,941 patent/US20190110974A1/en not_active Abandoned
- 2017-06-27 WO PCT/US2017/039506 patent/WO2018005494A1/en active Application Filing
-
2020
- 2020-12-17 US US17/125,572 patent/US20210228468A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3364942A1 (en) | 2018-08-29 |
EP3364942A4 (en) | 2019-07-17 |
US20210228468A1 (en) | 2021-07-29 |
WO2018005494A1 (en) | 2018-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Fazil et al. | Bisphosphonates: therapeutics potential and recent advances in drug delivery | |
Greish | Enhanced permeability and retention effect for selective targeting of anticancer nanomedicine: are we there yet? | |
HRP20170056T2 (en) | Low frequency glatiramer acetate therapy | |
JP2015187125A5 (en) | ||
WO2006008639A8 (en) | Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody | |
JP5639604B2 (en) | Pharmaceutical composition for inhibiting inflammation | |
CN107427469A (en) | solid oral dosage form | |
JP2016514132A5 (en) | ||
AU2015275237B2 (en) | Compositions and methods for treating joints | |
BR112013010829B1 (en) | INTRAVENOUS PHARMACEUTICAL COMPOSITION TO PROVIDE RELIEF OF PAIN AND/OR INFLAMMATION | |
US20220098331A1 (en) | Kits and methods of using hyaluronidase to modify polysaccharide fillers and delivery systems | |
Ehinger et al. | Bioequivalence and tolerability assessment of a novel intravenous ciclosporin lipid emulsion compared to branded ciclosporin in Cremophor® EL | |
JP6441825B2 (en) | Composition for maintaining efficacy of filler | |
US20210228468A1 (en) | Kits and methods of using ascorbates to modify polysaccharide fillers and delivery systems | |
Su et al. | Treatment of chemotherapy-induced neutropenia in a rat model by using multiple daily doses of oral administration of G-CSF-containing nanoparticles | |
de Vasconcelos Carvalho et al. | Association of aesthetic and orthodontic treatment in Parry-Romberg syndrome | |
WO2016154277A1 (en) | Kits and methods of using enzymes to modify polysaccharide fillers and delivery systems | |
Zhou et al. | The critical interaction between valproate sodium and warfarin: case report and review | |
Schanz et al. | Mirror, mirror on the wall: hypercalcemia as a consequence of modern cosmetic treatment with liquid silicone | |
Cho et al. | Pharmacokinetics and safety of two voriconazole formulations after intravenous infusion in healthy Korean volunteers | |
WO2019133166A1 (en) | Hyaluronidase for the prevention, treatment, reduction and/or abolishment of cerebral edema and intracranial pressure | |
Yassin et al. | Thrombopoietin-receptor agonists for adult patients with immune thrombocytopenia: a narrative review and an approach for managing patients fasting intermittently | |
Zhou et al. | The critical interaction between valproate sodium and warfarin: case report and | |
CN105477628A (en) | Anticancer composition and uses thereof | |
US20230293477A1 (en) | Method of treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ADVANCED AESTHETIC TECHNOLOGIES, INC., MASSACHUSET Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BURTT, RICHARD;REEL/FRAME:047451/0354 Effective date: 20181107 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |